Urine lipoarabinomannan in HIV uninfected, smear negative, symptomatic TB patients: effective sample pretreatment for a sensitive immunoassay and mass spectrometry

Abstract Our study sought to determine whether urine lipoarabinomannan (LAM) could be validated in a sample cohort that consisted mainly of HIV uninfected individuals that presented with tuberculosis symptoms. We evaluated two tests developed in our laboratory, and used them on clinical samples from...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anita G. Amin, Prithwiraj De, Barbara Graham, Roger I. Calderon, Molly F. Franke, Delphi Chatterjee
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/38bf040b420a4999893c1102456270ff
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:38bf040b420a4999893c1102456270ff
record_format	dspace
spelling	oai:doaj.org-article:38bf040b420a4999893c1102456270ff2021-12-02T14:06:57ZUrine lipoarabinomannan in HIV uninfected, smear negative, symptomatic TB patients: effective sample pretreatment for a sensitive immunoassay and mass spectrometry10.1038/s41598-021-82445-42045-2322https://doaj.org/article/38bf040b420a4999893c1102456270ff2021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-82445-4https://doaj.org/toc/2045-2322Abstract Our study sought to determine whether urine lipoarabinomannan (LAM) could be validated in a sample cohort that consisted mainly of HIV uninfected individuals that presented with tuberculosis symptoms. We evaluated two tests developed in our laboratory, and used them on clinical samples from Lima, Peru where incidence of HIV is low. ELISA analysis was performed on 160 samples (from 140 adult culture-confirmed TB cases and 20 symptomatic TB-negative child controls) using 100 μL of urine after pretreatment with Proteinase K. Two different mouse monoclonal antibodies-CS35 and CHCS9-08 were used individually for capture of urine LAM. Among cases, optical density (OD450) values had a positive association with higher bacillary loads. The 20 controls had negative values (below the limit of detection). The assay correctly identified all samples (97–100% accuracy confidence interval). For an alternate validation of the ELISA results, we analyzed all 160 urine samples using an antibody independent chemoanalytical approach. Samples were called positive only when LAM surrogates—tuberculostearic acid (TBSA) and d-arabinose (d-ara)—were found to be present in similar amounts. All TB cases, including the 40 with a negative sputum smear had LAM in detectable quantities in urine. None of the controls had detectable amounts of LAM. Our study shows that urinary LAM detection is feasible in HIV uninfected, smear negative TB patients.Anita G. AminPrithwiraj DeBarbara GrahamRoger I. CalderonMolly F. FrankeDelphi ChatterjeeNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Anita G. Amin Prithwiraj De Barbara Graham Roger I. Calderon Molly F. Franke Delphi Chatterjee Urine lipoarabinomannan in HIV uninfected, smear negative, symptomatic TB patients: effective sample pretreatment for a sensitive immunoassay and mass spectrometry
description	Abstract Our study sought to determine whether urine lipoarabinomannan (LAM) could be validated in a sample cohort that consisted mainly of HIV uninfected individuals that presented with tuberculosis symptoms. We evaluated two tests developed in our laboratory, and used them on clinical samples from Lima, Peru where incidence of HIV is low. ELISA analysis was performed on 160 samples (from 140 adult culture-confirmed TB cases and 20 symptomatic TB-negative child controls) using 100 μL of urine after pretreatment with Proteinase K. Two different mouse monoclonal antibodies-CS35 and CHCS9-08 were used individually for capture of urine LAM. Among cases, optical density (OD450) values had a positive association with higher bacillary loads. The 20 controls had negative values (below the limit of detection). The assay correctly identified all samples (97–100% accuracy confidence interval). For an alternate validation of the ELISA results, we analyzed all 160 urine samples using an antibody independent chemoanalytical approach. Samples were called positive only when LAM surrogates—tuberculostearic acid (TBSA) and d-arabinose (d-ara)—were found to be present in similar amounts. All TB cases, including the 40 with a negative sputum smear had LAM in detectable quantities in urine. None of the controls had detectable amounts of LAM. Our study shows that urinary LAM detection is feasible in HIV uninfected, smear negative TB patients.
format	article
author	Anita G. Amin Prithwiraj De Barbara Graham Roger I. Calderon Molly F. Franke Delphi Chatterjee
author_facet	Anita G. Amin Prithwiraj De Barbara Graham Roger I. Calderon Molly F. Franke Delphi Chatterjee
author_sort	Anita G. Amin
title	Urine lipoarabinomannan in HIV uninfected, smear negative, symptomatic TB patients: effective sample pretreatment for a sensitive immunoassay and mass spectrometry
title_short	Urine lipoarabinomannan in HIV uninfected, smear negative, symptomatic TB patients: effective sample pretreatment for a sensitive immunoassay and mass spectrometry
title_full	Urine lipoarabinomannan in HIV uninfected, smear negative, symptomatic TB patients: effective sample pretreatment for a sensitive immunoassay and mass spectrometry
title_fullStr	Urine lipoarabinomannan in HIV uninfected, smear negative, symptomatic TB patients: effective sample pretreatment for a sensitive immunoassay and mass spectrometry
title_full_unstemmed	Urine lipoarabinomannan in HIV uninfected, smear negative, symptomatic TB patients: effective sample pretreatment for a sensitive immunoassay and mass spectrometry
title_sort	urine lipoarabinomannan in hiv uninfected, smear negative, symptomatic tb patients: effective sample pretreatment for a sensitive immunoassay and mass spectrometry
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/38bf040b420a4999893c1102456270ff
work_keys_str_mv	AT anitagamin urinelipoarabinomannaninhivuninfectedsmearnegativesymptomatictbpatientseffectivesamplepretreatmentforasensitiveimmunoassayandmassspectrometry AT prithwirajde urinelipoarabinomannaninhivuninfectedsmearnegativesymptomatictbpatientseffectivesamplepretreatmentforasensitiveimmunoassayandmassspectrometry AT barbaragraham urinelipoarabinomannaninhivuninfectedsmearnegativesymptomatictbpatientseffectivesamplepretreatmentforasensitiveimmunoassayandmassspectrometry AT rogericalderon urinelipoarabinomannaninhivuninfectedsmearnegativesymptomatictbpatientseffectivesamplepretreatmentforasensitiveimmunoassayandmassspectrometry AT mollyffranke urinelipoarabinomannaninhivuninfectedsmearnegativesymptomatictbpatientseffectivesamplepretreatmentforasensitiveimmunoassayandmassspectrometry AT delphichatterjee urinelipoarabinomannaninhivuninfectedsmearnegativesymptomatictbpatientseffectivesamplepretreatmentforasensitiveimmunoassayandmassspectrometry
_version_	1718391955646316544

Urine lipoarabinomannan in HIV uninfected, smear negative, symptomatic TB patients: effective sample pretreatment for a sensitive immunoassay and mass spectrometry

Ejemplares similares